# Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

> **NCT05534087** · PHASE3 · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 236 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** mFOLFIRINOX-FOLFIRI intensified chemotherapy
- **DRUG:** FOLFOX or CAPOX adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT05534087
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05534087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05534087, "Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05534087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*